# Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies

> **NCT01499147** · NA · COMPLETED · sponsor: **University of Illinois at Chicago** · enrollment: 100 (actual)

## Conditions studied

- Acute Myeloid Leukemia
- Acute Leukemia
- Chronic Myelogenous Leukemia
- Malignant Lymphoma
- Hodgkin's Disease
- Multiple Myeloma
- Lymphocytic Leukemia
- Myeloproliferative Disorder
- Polycythemia Vera
- Myelofibrosis
- Aplastic Anemia

## Interventions

- **DRUG:** fludarabine/busulfan
- **DRUG:** fludarabine/ melphalan
- **DRUG:** ATG

## Key facts

- **NCT ID:** NCT01499147
- **Lead sponsor:** University of Illinois at Chicago
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-02
- **Primary completion:** 2013-05
- **Final completion:** 2013-05
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2018-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01499147

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01499147, "Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01499147. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*